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A Novel, Stable, Estradiol-
Stimulating, Osteogenic Yam 
Protein with Potential for the 
Treatment of Menopausal 
Syndrome
Kam Lok Wong1, Yau Ming Lai2, Ka Wan Li3, Kai Fai Lee4, Tzi Bun Ng5, Ho Pan Cheung1, 
Yan Bo Zhang1, Lixing Lao1, Ricky Ngok-Shun Wong6, Pang Chui Shaw7, Jack Ho Wong1, 5, 
Zhang-Jin Zhang1, Jenny Ka Wing Lam8, Wen-cai Ye9 & Stephen Cho Wing Sze1
A novel protein, designated as DOI, isolated from the Chinese yam (Dioscorea opposita Thunb.) could 
be the first protein drug for the treatment of menopausal syndrome and an alternative to hormone 
replacement therapy (HRT), which is known to have undesirable side effects. DOI is an acid- and 
thermo-stable protein with a distinctive N-terminal sequence Gly-Ile-Gly-Lys-Ile-Thr-Thr-Tyr-Trp-Gly-
Gln-Tyr-Ser-Asp-Glu-Pro-Ser-Leu-Thr-Glu. DOI was found to stimulate estradiol biosynthesis in rat 
ovarian granulosa cells; induce estradiol and progesterone secretion in 16- to 18-month-old female 
Sprague Dawley rats by upregulating expressions of follicle-stimulating hormone receptor and 
ovarian aromatase; counteract the progression of osteoporosis and augment bone mineral density; 
and improve cognitive functioning by upregulating protein expressions of brain-derived neurotrophic 
factor and TrkB receptors in the prefrontal cortex. Furthermore, DOI did not stimulate the 
proliferation of breast cancer and ovarian cancer cells, which suggest it could be a more efficacious 
and safer alternative to HRT.
Menopausal syndrome refers to the symptoms experienced by women during menopause, such as hot 
flushes, mood disorders, night sweats, depression, nervous tension, and insomnia1,2. Menopause also puts 
women at increased risk of cardiovascular disease and osteoporosis. The total worldwide population of 
postmenopausal women was 476 million in 1990 as reported by the World Health Organization, and 
477 million in 1998 as reported by the North American Menopausal Society. By 2030, it is predicted 
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that this population will reach 1200 million3. The current approach for relieving menopausal syndrome 
is hormone replacement therapy (HRT), which restores the endogenous estrogen level using supple-
mentary exogenous estrogen with or without progestin4,5. Estradiol and conjugated estrogens have been 
proven effective in the treatment of vasomotor symptoms, urogenital atrophy, and irregular menstrual 
bleeding6–10. However, HRT can have side effects, which need to be taken into consideration. The risk of 
endometrial cancer has been shown to be associated with HRT in a dose-dependent manner, and even 
treatments using a low dose of a weak estrogen may induce endometrial cancer11. HRT is also believed 
to be associated with breast cancer, ovarian cancer12, venous thromboembolism, and stroke13. Although 
formulations of HRT have shown improvements in recent years, its side effects require further evalua-
tion in clinical studies. Therefore, safe and effective therapeutics for menopausal syndrome are needed. 
Tissue-specific estradiol-stimulating components and potential drug candidates for the treatment of 
menopausal syndrome would be desirable as safer alternatives to HRT.
Yam tubers, belonging to the monocotyledonous Dioscorea genus, are a major staple food crop 
in tropical and subtropical regions, with an annual world production of around 58.1 million tons in 
201214. The Dioscorea family has more than 600 species found throughout the world and 93 are found 
in China, of which 13 are edible and are widely consumed as a staple food or tonic food15. Rhizoma of 
Dioscorea opposita (Shanyao) has been included in the Pharmacopoeia of the People’s Republic of China 
as a Chinese herbal medicine. It is by far the most commonly used Dioscorea species for improving 
female health and for regulating menstruation16. The chemical composition and pharmacology of many 
Dioscorea species have been extensively studied. Dioscin (glycoside form of diosgenin) is a type of sap-
onin isolated from the n-butanol fraction of extracts from Dioscorea batatas DECNE, which was found 
to induce the release of growth hormones from rat pituitary cells and elevate plasma levels in rats17. 
Diosgenin displays impressive pharmacological properties18 and is structurally similar to the precursor 
of steroid hormones19. Diosgenin can be converted to steroid hormones by industrial processes20,21, but 
cannot be biochemically transformed into steroid hormones by the human body19. Interestingly, previous 
clinical investigations indicated that Dioscorea extract was effective in mitigating menopausal syndrome 
by elevating serum estrogen levels22. Therefore, the estrogenic ability exhibited by Dioscorea tubers needs 
to be identified and further investigated to uncover the mechanisms involved. Our pilot study found that 
total protein extracts of Dioscorea opposita exhibited stimulating effects on estrogen biosynthesis in rat 
ovarian granulosa cells.
In this study, we aimed to isolate and characterize the bioactive protein, designated DOI, from 
Dioscorea opposita. The DOI protein of Dioscorea opposita was extracted and purified by fast protein 
liquid chromatography (FPLC). DOI was chemically characterized by SDS-PAGE and silver staining, 
and by N-terminal and partial amino acid sequencing. DOI was biologically characterized by in vitro 
estrogenic assay; acid, alkali and thermal stability tests; viability assays in ovarian granulosa cells, cancer 
cells and immune cells to evaluate the cancer risk; and chitinase activity assay. Results obtained from 
the biological characterization demonstrated that DOI had potent estrogen-stimulating activity. The effi-
cacy of DOI for treating physiological states characterized by estrogen deficiency (e.g., menopause) was 
evaluated by determining the serum estrogen and progesterone levels, brain derived neurotrophic factor 
(BDNF) levels, and bone mineral density in a menopausal rat model treated with DOI. We also studied 
the molecular actions of DOI in relation to ovarian steroidogenesis including ovarian follicle-stimulating 
hormone receptor (FSHR), protein kinase A, B, C (PKA, PKB, PKC) and aromatase, and cognitive func-
tions including BDNF and TrkB gp145.
Results
DOI protein extraction and column purification. Crude protein extracts were obtained from the 
Chinese yam, Dioscorea opposita Thunb. The protein preparations were separated by chromatography 
on a HiPrep 16/10 DEAE FF column using an AKTA Purifier Fast Protein Liquid Chromatography 
(FPLC) system (Fig.  1a). Fraction D3 (third peak) had estrogen-stimulating activity and was collected 
and dialyzed. It was purified on a HiPrep 16/10 Phenyl FF (high sub) column by FPLC. Active fraction 
P1 (Fig. 1b) was dialyzed and further purified on a Superdex 75 10/300 GL column by FPLC. The purified 
active protein (fraction S1), designated as DOI, was obtained at a yield of 0.36% of the total soluble pro-
teins extracted from Dioscorea opposita Thunb. The purification steps are summarized in Supplementary 
Table S1.
Chemical characterization of DOI. The high purity of the isolated DOI protein was verified 
and DOI was visualized as a single band in 15% SDS-PAGE and silver staining (Fig.  1d). The molec-
ular weight of DOI was 32.5 kDa as measured by size-exclusion chromatography and SDS-PAGE 
(Supplementary Table S2), and was 33.5 kDa as measured by mass spectrometry (Fig.  1e). The 
N-terminal sequence of DOI was GIGKITTYWGQYSDEPSLTE as determined by Edman deg-
radation. A partial internal amino acid sequence of DOI was K S F Y T R S N F L E A V S A Y P G F G T­
K R E I A A Y F A H V T H G P M Q L S W N Y N Y I D A G K E L H F D G L N D P D I V G RDPIISFKTSLWFWIRK 
GVQYVILDPNQGFGATIRIINGGQECDGHNTAQMMARVGYYQEYCAQ as determined by mass 
spectrometry.
BLAST analysis of the N-terminal sequence of DOI in NCBI showed a high E-value (>10−3) that 
indicated it was a novel protein. The results showed DOI was a member of the chitinase-like superfamily 
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(Supplementary Table S3). BLAST analysis of the partial amino acid sequence of DOI revealed that 
it had high homology with the 27.9-kDa chitinase (AAB23692.1) from Dioscorea japonica23 and the 
31.4-kDa chitinase (BAC56863.1) from Dioscorea oppositifolia24. Mass spectrometry analysis of tryptic 
peptides from DOI identified 10 peptides by MaxQuant that are matched to the acidic endochitinase 
from Dioscorea japonica. The identified peptides are highlighted in bold in the partial sequence of acidic 
endochitinase. Our isolated DOI protein had a comparable molecular weight of 33.5 kDa as measured by 
mass spectrometry (Fig. 1e). The N-terminal sequence of the isolated DOI showed differences from the 
31.4-kDa BAC56863.1 chitinase from Dioscorea oppositifolia24. In addition, the chitinase activity of DOI 
was negligible using three different substrates, 4-nitrophenyl N,N′ -diacetyl-β-D-chitobioside (N6133), 
4-nitrophenylN-acetyl-β-D-glucosaminide (9376) and 4-nitrophenyl β-D-N,N′ ,N′ ′ -triacetylchitotriose 
(N8638), in the chitinase assay (Fig.  2d). These differences may be due to alternative splicing and 
post-translational modifications. This data suggests that DOI might be a novel protein.
Biological characterization of DOI. The DOI protein did not have any hemagglutinating activity, 
which suggested it was not a lectin. DOI (1 to 10 nM) displayed estrogen-stimulating activity in rat 
ovarian granulosa cells but not at concentrations of 100 nM (Fig. 2). DOI (10 nM) showed acid stability 
as its estrogen-stimulating activity remained intact after treatment with HCl (0.01–1 M) (Fig.  2a) and 
also showed themo-stabilty at 80 °C (Fig.  2c), but it did not show alkali stability in NaOH (0.01–1 M) 
Figure 1. (a) Purification of DOI on a HiPrep 16/10 DEAE FF column. (b) Fraction D3 was further purified 
on a HiPrep 16/10 Phenyl FF (high sub) column. (c) Fraction P1 was further purified on a Superdex 75 
10/300 GL column and fraction S1 contained the DOI protein. (d) 15% Native PAGE of DOI (left) and 15% 
SDS-PAGE of DOI (right). The DOI protein was visualized by silver staining. (e) Size measurement of DOI 
by mass spectrometry.
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(Fig. 2b). As mentioned, DOI did not show chitinase activity compared with the positive chitinase con-
trol (Fig. 2d).
Cell viability using MTT assay was performed to evaluate the tissue-specificity and toxicity of DOI 
in various cell types, including MCF-7 breast cancer cell line, OVCA-429 ovarian cancer cell line, mouse 
splenocytes, and rat ovarian granulosa cells. The results showed DOI increased the viability of mouse 
splenocytes and rat ovarian granulosa cells, but decreased the viability of MCF-7 and OVCA-429 cells in 
a dose-dependent manner (Fig. 3). The reduction in the viability of normal cells is a key index of toxicity 
after exposure to a toxic substance. The DOI protein isolated from edible Chinese yam did not cause any 
apparent toxicity in vitro.
Estradiol-stimulating effect of DOI in vitro. To determine the estradiol-stimulating effect of DOI, 
we measured the estradiol levels in cell culture medium of DOI-treated rat ovarian granulosa. Granulosa 
cells treated with DOI (1 and 10 nM) had significantly increased estradiol biosynthesis (Fig.  4A) and 
aromatase expression (Fig. 4b) compared to the control, with Forskolin used as a positive control. DOI 
(10 nM) had maximal effect on stimulating both estradiol production and aromatase expression, whereas 
Figure 2. Estrogen-stimulating activity of (a) HCl-, (b) NaOH-, (c) heat-treated DOI on granulosa cells. 
Results are expressed as means ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control 
group (un-paired t-test). (d) Chitinase activity of DOI. Results are expressed as means ± SEM (n = 3). 
**p < 0.01, ***p < 0.001 compared with the positive chitinase control (un-paired t-test). N9376: 4-Nitrophenyl 
N-acetyl-β-D-glucosaminide used to detect exochitinase activity (β-N-acetylglucosaminidase activity); 
N8638: 4-Nitrophenyl β-D-N, N’, N”triacetylchitotriose used to detect endochitinase activity; and N6133: 
4-Nitrophenyl N, N′ -diacetyl-β-D-chitobioside used to detect exochitinase activity (chitobiosidase activity).
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DOI (100 nM) did not show any estrogen-stimulating activity compared with the control. The FSHR 
expression also increased with DOI (1 to 100 nM) treatments (Fig. 4c).
In the presence of PKA inhibitor (PKAi), estradiol levels in the culture medium of granulosa cells 
were significantly decreased in both the control group and DOI-treated group (Fig. 4d). PKAi decreased 
the DOI (10 nM)-induced estrogen-stimulating activity by one-fold (Fig. 4d). Both PKB and PKC inhib-
itors (PKBi and PKCi) significantly decreased estradiol levels in the culture medium of the DOI-treated 
groups, but did not affect the estradiol levels in the control group (Fig.  4e,f). Our results showed the 
estradiol-stimulating effect of DOI was abolished in the FSHR-attenuated ovarian granulosa cell model 
(Fig. 4g).
Estradiol-stimulating effect of DOI in vivo. To determine the estradiol-stimulating effect of DOI, 
we measured the serum estradiol and progesterone levels in our rat model. The levels of estradiol and 
progesterone reached their peaks after 6 weeks of DOI (5 mg/kg) treatment (Fig. 5). However, treatment 
with the highest concentration of DOI (10 mg/kg) for 6 weeks did not significantly increase estradiol 
and progesterone levels compared with the control. Premarin used in HRT also increased estradiol bio-
synthesis.
The body weights of the Sprague Dawley (SD) rats did not significantly change during the DOI and 
Premarin treatments (Fig. S1). A reduction in body weight could be a sensitive index of toxicity after 
the animal has been exposed to a toxic substance. These results indicate that DOI did not cause any 
apparent toxicity in vivo. The ratio of final ovarian weight to final total body weight remained steady 
after treatment with DOI (2.5 and 5 mg/kg) compared with the control, but treatment with 10 mg/kg DOI 
and Premarin increased the ovary weight, with the ratio increasing from 0.032% to 0.047% and 0.048% 
(p < 0.05), respectively (Fig. S2).
Determination of the estrogen-related gene expressions in vivo. The estrogen-related gene 
expression levels in our rat model were determined by real-time PCR. The mRNA expressions of both 
CYP-19 and FSHR in the ovaries of SD rats were significantly increased after treatment with DOI and 
Premarin (Fig. 6A,B). The groups treated with 2.5 mg/kg DOI had the highest mRNA expressions among 
the three DOI dosage groups compared with the control group and the effect was not dose-dependent. 
The mRNA expressions of both PKA and PKB in the ovaries of SD rats were significantly increased after 
treatment with DOI (Fig. 7A,B).
Figure 3. Viability of (a) MCF-7 breast cancer cells, (b) OVCA-429 ovarian cancer cells, (c) mouse 
splenocytes, and (d) ovarian granulosa cells after treatment with DOI for 48 h. Results are expressed as 
means ± SEM (n = 3). **p < 0.01, ***p < 0.001 compared with the control group (un-paired t-test).
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Determination of the estrogen-related protein expressions in vivo. The estrogen-related pro-
tein expression levels in our rat model were determined by Western blotting analysis. The levels of 
ovarian aromatase were significantly upregulated in the groups treated with DOI (2.5 and 5 mg/kg), 
whereas the groups treated with 10 mg/kg DOI had similar levels to the control. The Premarin-treated 
Figure 4. (a) Stimulatory activity of DOI on estrogen biosynthesis in granulosa cells. Protein expression of 
(b) aromatase and (c) follicle-stimulating hormone receptor (FSHR) in ovarian granulosa cells. Results are 
expressed as means ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control group (un-
paired t-test). Effects of (d) protein kinase A inhibitor (PKAi), (e) protein kinase B inhibitor (PKBi), and 
(f) protein kinase C inhibitor (PKCi) on the estrogen-stimulating effect of DOI on ovarian granulosa cells. 
(g) Effects of DOI on FSHR-attenuated ovarian granulosa cells after 12 h treatment. Results are expressed as 
means ± SEM (n = 3). *p < 0.05, **p < 0.01 compared with the control group (un-paired t-test).
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group had significantly attenuated protein expression level of ovarian aromatase (Fig. 6c,d). The protein 
expression level of breast aromatase was not upregulated in all DOI treatment groups both in vitro and 
in vivo (Fig. 6e,f). The protein expression level of ovarian FSHR was not affected by Premarin treatment, 
whereas the expression level was significantly enhanced with DOI (2.5, 5, and 10 mg/kg). The protein 
expression level of PKA was significantly upregulated in the groups treated with 10 mg/kg DOI (Fig. 7D).
Measurement of bone mineral density and microarchitecture by microCT scanning. To 
determine the osteogenic effects of DOI, we examined the bone mineral density and microarchitecture, 
which is known to be altered during aging and menopause. Volume rendered images at the 2nd lumbar 
vertebra (L2) in 18-month-old female SD rats treated with different dosages of DOI are shown in Fig. 8. 
All DOI treatment groups demonstrated an increase in the apparent bone mineral density of vertebra 
L2 compared with the control group. The apparent bone mineral density was significantly augmented 
following DOI (2.5 and 5 mg/kg) treatments (Fig. 9a). DOI, but not Premarin, had a tendency to increase 
the bone volume fraction of vertebra L2. DOI (2.5 mg/kg) significantly elevated the bone volume frac-
tion compared with the control group (Fig. 9b). The trabecular number of vertebra L2 showed a slight 
increase after the DOI treatments, but the increase was not significant compared with the control group 
(Fig. 9c). Treatment with DOI (2.5 and 5 mg/kg) significantly enhanced the trabecular thickness of ver-
tebra L2 compared with the control group (Fig. 9d). All the DOI treatment groups showed a decrease 
in the structure model index of vertebra L2 compared with the control group, and this reduction was 
Figure 5. (a) Serum estradiol and (b) progesterone levels in Sprague Dawley rats after treatment with DOI 
for 2, 4, and 6 weeks. Results are expressed as means ± SEM (n = 6). *p < 0.05, **p < 0.01 compared with week 
2 controls;+p < 0.05 compared with week 4 controls; and #p < 0.05, ##p < 0.01 compared with week 6 controls 
(un-paired t-test). Ctl: control group received daily intraperitoneal injections of PBS; Premarin: positive 
control group received daily Premarin (12.4 mg/kg) by oral administration; DOI groups: DOI-treated groups 
received daily intraperitoneal injections of DOI (2.5, 5, and 10 mg/kg).
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significant in the 2.5 mg/kg DOI treatment group (Fig.  9e). The trabecular separation of vertebra L2 
did not show any significant changes following the treatments, with the exception of the 5 mg/kg DOI 
treatment (Fig. 9f).
Figure 6. mRNA expression of (a) ovarian CYP-19 and (b) follicle-stimulating hormone receptor (FSHR), 
and protein expression of (c) ovarian aromatase, (d) ovarian FSHR, and (e) breast aromatase in Sprague 
Dawley rats after treatment with DOI for 6 weeks. (f) Protein expression of aromatase in DOI-treated 
MCF-7 breast cancer cell line. Results are expressed as means ± SEM (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 
compared with the control group (One-way ANOVA followed by Dunnett’s Multiple Comparison Test). 
Ctl: control group received daily intraperitoneal injections of PBS; Premarin: positive control group 
received daily Premarin (12.4 mg/kg) by oral administration; DOI group: DOI-treated groups received daily 
intraperitoneal injections of DOI (2.5, 5, and 10 mg/kg).
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9Scientific RepoRts | 5:10179 | DOi: 10.1038/srep10179
Detection of the protein levels of BDNF and TrkB gp145. To determine the effects of DOI treat-
ments on cognitive functions, we measured BDNF and its receptor TrkB gp145 in our rat model. The 
BDNF concentration in the prefrontal cortex was significantly increased after treatment with 5 mg/kg 
DOI (Fig. 10a,b). The other treatment groups did not show any significant changes. The DOI (2.5 and 
5 mg/kg) and Premarin treatments caused significant increases in the expression of TrkB gp145 receptors 
(Fig. 10c).
Figure 7. mRNA expression of (a) PKA, (b) PKB and (c) PKC, and protein expression of (d) PKA, (e) PKB 
and (f) PKC in ovaries of Sprague Dawley rats after treatment with DOI for 6 weeks. Results are expressed 
as means ± SEM (n = 3 for mRNA; n = 6 for protein). *p < 0.05, **p < 0.01, ***p < 0.001 compared with control 
group (one-way ANOVA and un-paired t-test, respectively).
www.nature.com/scientificreports/
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Discussion
Here, we present the first report of a bioactive principle of Chinese yam that can elevate estradiol biosyn-
thesis. We extracted a novel protein, designated as DOI, from Dioscorea opposita with a molecular weight 
of 33.5 kDa as measured by mass spectrometry. We biologically characterized DOI and elucidated its 
potential pharmacological activity. Two similar proteins of interest, dioscorin25 and DJ23, have been pre-
viously isolated from Dioscorea batatas Decne and Dioscorea japonica, respectively. In addition, dioscorin 
has also been isolated from other Dioscorea species such as Dioscorea alata26,27. These proteins isolated 
from yam have different molecular weights and N-terminal sequences, as well as different lectin, antiox-
idative, immunomodulating, carbonic anhydrase, trypsin inhibiting, chitinase, and estrogen-stimulating 
activities compared with DOI (Supplementary Table S4).
The stability of proteins can be affected by high temperatures, acid, alkali conditions, enzymatic deg-
radation, and clearance mechanisms. We found that the estrogen-stimulating activity of DOI in ovarian 
granulosa cells was preserved in DOI treated with HCl (up to 1 M), but this activity was lost with NaOH 
(0.01–1 M) treatment (Fig. 2a,b). Furthermore, DOI could withstand temperatures up to 80 °C, which sig-
nificantly increased the activity of DOI (Fig. 2c). Our results indicated that DOI treated with 0.1 M HCl 
at 80 °C might expose an active site involving a shorter amino acid sequence that has increased activity. 
These findings could be important for the preparation of more potent DOI-based therapeutics in future 
studies. DOI itself could be developed into protein therapeutics that exploit its estrogen-stimulating 
activity. In addition, its half-life and absorption could be prolonged, and its degradation under acidic 
conditions and high temperatures could be retarded. Nowadays, these issues can be addressed by many 
formulations and technologies for drug delivery, such as polyethylene glycol (PEG)28.
Menopause together with general aging are associated with a decline in immune function. During 
aging, changes in the immune system such as altered immune tolerance, increase of auto-antibodies, 
decline in function of natural killer cells, T lymphocytes and B lymphocytes have been reported29. Estrogen 
deficiency after menopause is thought to be related to an increase in the levels of pro-inflammatory 
serum markers, a reduction in CD4 T lymphocytes and B lymphocytes, and a decrease in the cytotoxic 
activity of natural killer cells29–31. Our in vitro study showed that DOI could stimulate the viability of 
mouse splenocytes (Fig.  3). DOI could be beneficial in preventing the decline in immune functions 
during menopause.
The gradual decline in the secretion of ovarian estradiol (E2) and progesterone (P) are hallmarks of 
menopause32, which also represents the breakdown of normal hypothalamic-pituitary-ovarian (H-P-O) 
function through loss of feedback regulation of ovarian steroids. Estrogen biosynthesis is catalyzed 
Figure 8. Volume rendered images of L2 in 16- to 18-month-old female SD rats given different treatments 
(image presented with BV/TV closest to the group mean value).
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Figure 9. (a) Apparent trabecular bone mineral density, (b) bone volume fraction, (c) trabecular number, 
(d) trabecular thickness, (e) structure model index, and (f) trabecular separation of vertebra L2 of Sprague 
Dawley rats after treatment with DOI for 6 weeks. Results are expressed as means ± SEM (n = 6; except 
Premarin group, where n = 3). *p < 0.05, **p < 0.01 compared with the control group (unpaired t-test). Ctl: 
control group received daily intraperitoneal injections of PBS; Premarin positive control group received daily 
Premarin (12.4 mg/kg) by oral administration; DOI group: DOI-treated groups received daily intraperitoneal 
injections of DOI (2.5, 5, and 10 mg/kg).
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by aromatase in ovarian granulosa cells33. In non-menopausal women, high circulating levels of 
follicle-stimulating hormone (FSH) induce estrogen secretion by activating the aromatase-encoding gene 
Cyp1934. In aging and menopause, there is a decline in ovarian function and the activity of the ovarian 
aromatase35. Although the circulating level of FSH remains high for several years after menopause, this 
does not induce the increase of circulating estrogen level. A progressive deterioration in ovarian steroi-
dogenesis appears to be a major factor associated with menopause35. Estradiol secretion from ovarian 
granulosa cells could reveal steroidogenesis and function of the ovary36,37. Ovarian granulosa cells are 
often used as a cell model for the evaluation of ovarian steroidogenesis36,37. FSH is important for gran-
ulosa cell steroidogenesis by increasing the expression and activity of aromatase resulting in increased 
biosynthesis of estradiol38. In the classically described mechanism of the function of FSHR, ligand bind-
ing results in the activation of adenylate cyclase, increased production of cAMP, and activation of PKA 
and PKB39–41, which then directly influences the expression and activation of aromatase and PKC as a 
negative regulator42.
The results from our in vitro study demonstrated that DOI treatment could upregulate FSHR and 
aromatase expression in ovarian granulosa cells, indicating the increased estradiol biosynthesis could 
be via the FSHR-aromatase pathway (Fig. 4a–c). Results of the protein kinase inhibition assay suggested 
that PKA, PKB, and PKC were involved, because the activity of DOI was abolished by inhibitors of 
PKA, PKB, and PKC (Fig. 4d,e). Furthermore, the estradiol-stimulating effect of DOI was abolished in 
the FSHR-attenuated ovarian granulosa cell model, confirming DOI promoted estradiol biosynthesis, at 
least, via interaction with FSHR (Fig. 4g).
A progressive deterioration in the neuroendocrine axis, including ovarian steroidogenesis, in female 
rats and women appears to be a major factor associated with typical reproductive aging43–48. To mimic 
the reproductive failure in menopausal women, we used 16- to 18-month-old female SD rats with low 
serum estrogen levels as the animal model, because the gradual decline of neuroendocrine function in 
rats is similar to humans. DOI could delay the onset of estrogen deficiency associated with aging when 
compared with their corresponding control groups (Fig. 5a). DOI induced an increase in serum estradiol 
and progesterone levels in vivo after treatment for 6 weeks in a dose-dependent manner. Peak levels of 
estradiol and progesterone occurred with a concentration of 5 mg/kg DOI, whereas the levels declined 
with a concentration of 10 mg/kg DOI (Fig. 5). This bell-shaped dose-response curve was found, espe-
cially for the stimulation of progesterone. Our in vivo experiments revealed the underlying mechanism 
for the increase in the estradiol levels could be via the upregulation of protein levels of FSHR, aromatase 
(Fig. 6), and PKA (Fig. 7d). This possible pathway for the action of DOI involving FSHR, PKA, and aro-
matase is also a classical pathway for steroidogenesis. Data from the Western blot analysis revealed that 
DOI (2.5 and 5 mg/kg) treatment upregulated aromatase in the ovary (Fig. 6c), but not in breast tissue 
(Fig. 6e) or MCF-7 breast cancer cells (Fig. 7f). In addition, DOI decreased the viability of MCF-7 breast 
cancer cells and OVCA-429 ovarian cancer cells in a dose-dependent manner. Thus, estrogen-stimulating 
activity of DOI is not expected to display any of the side effects of hormone replacement therapy such 
as the increased risk of breast and ovarian carcinogenesis.
Osteoporosis is one of the major menopausal symptoms, which is characterized by bone mass reduc-
tion and skeletal microarchitectural deterioration, resulting in an increased risk of fractures. The loss 
of ovarian hormones (estrogen and progesterone) during menopause is one of the major risk factors 
Figure 10. Protein levels of brain derived neurotrophic factor (BDNF) in (a) prefrontal cortex and (b) 
hippocampus of Sprague Dawley rats after treatment with DOI for 6 weeks. (c) Protein levels of TrkB  
gp145 receptor in prefrontal cortex of Sprague Dawley rats after treatment with DOI for 6 weeks. Results  
are expressed as means ± SEM (n = 6). *p < 0.05, **p < 0.01 compared with the control group (un-paired  
t-test). Ctl: control group received daily intraperitoneal injections of PBS; Premarin: positive control group 
received daily Premarin (12.4 mg/kg) by oral administration; DOI group: DOI-treated groups received daily 
intraperitoneal injections of DOI (2.5, 5, and 10 mg/kg).
www.nature.com/scientificreports/
13Scientific RepoRts | 5:10179 | DOi: 10.1038/srep10179
for osteoporosis, which causes increased bone resorption and decreased bone formation49,50 Bone 
remodeling increases substantially in the years after menopause, which contributes to age-related skel-
etal fragility in women51. It has been shown that trabecular bone mineral density, trabecular bone vol-
ume fraction, trabecular thickness, and trabecular number all decrease with age52. Also, a lower bone 
mass is primarily characterized by a smaller plate-to-rod ratio53. All these changes would weaken bone 
strength and increase the risk of osteoporotic fracture. The trabecular bone mineral density at the L2 
mid-vertebral body has been used for the clinical assessment of osteoporosis54, and we used this to 
evaluate the anti-osteoporotic effect of DOI in our study. We found that DOI had beneficial effects on 
the bone mineral density and microarchitecture in vivo. We observed increased bone mineral density, 
bone volume fraction, trabecular number and trabecular thickness, and decreased structure model index 
and trabecular separation of the vertebra L2 using high resolution microCT (Fig. 9a–f). These changes 
in bone density and microarchitecture favor the enhancement of bone strength55,56. The decrease in 
structure model index indicated an increase in the ratio of plate-shaped to rod-shaped trabeculae. The 
latter trabecular structure is dominant in osteoporosis57. The increase in plate-shaped trabeculae found 
in the present investigation indicated the bone may be less porous as reflected in the parallel decrease of 
trabecular separation. This suggests DOI could exert an anti-osteoporotic effect on the trabecular bone 
in vivo. Together with the effects on estradiol and progesterone biosynthesis, DOI might be a potential 
therapeutic agent for menopausal osteoporosis.
Cognitive decline is a common phenomenon experienced by menopausal women58. A recent study 
demonstrated that plasma BDNF level can be used as a biomarker for cognitive function in aging women59. 
Another study found BDNF was significantly decreased in older human subjects60. Administration of 
exogenous BDNF was found to offset some physiological or pathological age-associated changes in the 
central nervous system61. BDNF is widely expressed in the brain. It belongs to the neurotrophin family, 
which is a group of small basic secreted proteins that aid in the survival, maintenance, and plasticity of 
specific neuronal populations. In this study, treatment with DOI increased the protein expression levels 
of BDNF in the prefrontal cortex and hippocampus, and TrkB gp145 in the prefrontal cortex (Fig. 10). 
Thus, DOI could have beneficial effects because the prefrontal cortex is important for cognitive func-
tion62,63. However, the pharmacological effect might not be directly due to the DOI protein, as it cannot 
cross the blood brain barrier to reach the prefrontal cortex. The effect might be due to the increased 
serum estradiol levels, because it is thought that estradiol is neuroprotective and can increase the expres-
sion of BDNF64,65.
The exact mechanism of how DOI stimulates the biosynthesis of estradiol requires further inves-
tigation. Our data suggest that DOI might act on ovarian aromatase, but whether the upregulation of 
aromatase is a direct effect of DOI remains unknown. Therefore, the effect of aromatase inhibitor on the 
DOI-treated granulosa cells will need to be studied, which would help to confirm our proposed mech-
anism. Further studies on the stimulating effect of DOI on estradiol secretion using the ovariectomized 
SD rat model66 will help to elucidate whether the increased serum estradiol level was due to increased 
ovarian estradiol biosynthesis or was from other organs. In this study, the bell-shaped dose-response 
curves of the effects of DOI on estrogen biosynthesis in vitro (Fig. 4A) and in vivo (Fig. 5A) were meas-
ured. Further study with a wider range of DOI concentrations will be required to provide information 
about the most effective dosage of DOI.
Conclusion
The novel DOI protein isolated from Dioscorea opposita stimulated estradiol secretion by binding to 
FSHR, and upregulated the expression of ovarian FSHR and aromatase both in vitro and in vivo pre-
dominantly through the activation of PKA. DOI also induced the secretion of estradiol and progesterone 
in aged female SD rats. More importantly, DOI exhibited tissue-specific bioactivity as it enhanced the 
proliferation of splenocytes and ovarian granulosa cells, but did not stimulate the proliferation of breast 
cancer cells and ovarian cancer cells. Furthermore, DOI could upregulate protein expression levels of 
ovarian aromatase but not breast aromatase in vitro and in vivo. These results suggest that DOI could 
be a more efficacious and safer alternative to HRT for the treatment of menopausal syndrome. Apart 
from improving the hormonal status, DOI could be beneficial for menopausal osteoporosis and improve 
cognitive functioning. Findings from this study have been used to apply for patents (Patent Cooperation 
Treaty Patent Pub. No.: WO/2013/023617; U.S. Patent Pub. No.: US 20130217626 A1; European Patent 
Pub. No.: EP 2750684 A1; China Patent pub. No.: CN 103945854 A), and we are seeking industrial part-
ners for further research and future development of DOI as the first protein drug for the treatment of 
menopausal syndrome.
Methods
Protein extraction. Rhizomes of Dioscorea opposita were obtained from a market on Centre Street in 
Hong Kong. The tubers were authenticated by Dr Yanbo Zhang, one of the authors of this manuscript. The 
rhizomes were peeled and homogenized in an extraction buffer (5% acetic acid, 0.1% β-mercaptoethanol) 
in a ratio of 1:2 (w/v) for 3 h at 4 °C. The homogenate was centrifuged at 17700 g for 30 min at 4 °C. 
Ammonium sulfate was added to the supernatant to 80% saturation. The mixture was stirred at 4 °C over-
night and centrifuged at 17700 g for 1 h at 4 °C. The precipitated proteins were resuspended in Milli-Q 
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H2O. The protein extract was dialyzed against double-distilled H2O overnight and then ultra-centrifuged 
at 40000 g for 2 h at 4 °C. The supernatant was collected for further purification by FPLC.
Column purification of DOI protein. The supernatant was adjusted to a final concentration of 
100 mM Tris (pH 8.0) and was loaded on a HiPrep 16/10 DEAE FF column (GE Healthcare, Sweden) 
for purification using an AKTA Purifier (GE Healthcare, Sweden) FPLC system (Buffer A: 100 mM Tris, 
pH 8.0; Buffer B: 1 M NaCl, with 100 mM Tris, pH 8.0. Gradient 0% – 45% Buffer B). Fraction D3 was 
collected and dialyzed against double-distilled H2O overnight. Fraction D3 (Fig.  1a) was adjusted to 
50% Buffer B and loaded on a HiPrep 16/10 Phenyl FF (high sub) column (GE Healthcare, Sweden) 
for FPLC (Buffer A: Milli-Q H2O; Buffer B: 10 mM sodium phosphate, pH 7.0 with 1 M (NH4)2SO4. 
Gradient: 30% – 0% Buffer B). Fraction P1 (Fig. 1b) was collected and dialyzed against double-distilled 
H2O overnight and then lyophilized into powder form. The lyophilized powder was dissolved in 50 mM 
sodium phosphate (pH 7.2) containing 150 mM NaCl and then loaded on a Superdex 75 10/300 GL 
column (GE Healthcare, Sweden) for FPLC (Buffer A: 50 mM sodium phosphate, pH 7.2 with 150 mM 
NaCl. Flow rate = 0.6 mL/min). The column was calibrated with the above buffer using molecular mass 
markers: aprotinin (6500 Da), ovalbumin (44287 Da), and bovine serum albumin (66000 Da). Fraction 
S1 containing the DOI protein (Fig.  1c) was collected and dialyzed against double-distilled H2O over-
night and then lyophilized into powder form and stored at −20 °C for the biological characterization.
Chemical characterization of DOI. The molecular weight of DOI was determined by size-exclusion 
chromatography on a Superdex 75 10/300 GL column (GE Healthcare, Sweden), by mass spectrometry, 
and by 15% Native PAGE and 15% SDS-PAGE with silver staining. The N-terminal sequence was deter-
mined by Edman degradation using a 494 Procise Protein Sequencer/140C Analyzer (Applied Biosystems, 
Inc., USA) with the assistance of the Protein Facility of Iowa State University, USA. The N-terminal 
sequence was searched with BLAST. The partial amino acid sequence was measured by mass spectrome-
try with the support of the Proteomics Centre in the VU University, Amsterdam, the Netherlands. DOI 
(4.5 μg) was redissolved in 50 mM ammonium bicarbonate and incubated with 300 ng trypsin/Lys-C Mix 
(Mass Spec grade; Promega, USA) at 37 °C for 16 h, and then dried in a speedvac. Peptides were analyzed 
by nanoLC-MS/MS using an Ultimate 3000 LC system (Dionex, Thermo Scientific, CA, USA) coupled to 
the TripleTop 5600 mass spectrometer (Sciex, Ontario, Canada). Peptides were trapped on a PepMap 100 
C18 column (5 mm × 300 μm ID, 5-μm particle size; Dionex) and fractionated on a Alltima C18 column 
(200 mm × 100 μm ID, 3-μm particle size; Thermo Fisher Scientific, MA, USA). The acetonitrile concen-
tration in the mobile phase was increased from 5% to 40% in 30 min and to 90% in 3 min at a flow rate 
of 400 nL/min. The eluted peptides were electrosprayed into the TripleTop MS. The mass spectrometer 
was operated in a data-dependent mode with a single MS full scan (m/z 350-1200) followed by top 20 
MS/MS scan. The data were searched with MaxQuant using the UniProt/SwissProt plant database.
Biological characterization of DOI. Determination of estradiol-stimulating effect of DOI by in vitro 
estrogenic assay. Nine female Sprague Dawley rats (21 to 23 days old; 3 rats per group) were primed 
with 80 IU pregnant mare serum gonadotropin (PMSG; Sigma-Aldrich, USA) for 48 h to stimulate fol-
licular development. The rats were sacrificed and their ovaries were collected. The ovarian follicles were 
punctured with a 25-gauge needle to isolate granulosa cells. Cells in serum-free DME/F12 1:1 medium 
supplemented with 1% penicillin-streptomycin and 1% bovine serum albumin were seeded at a density 
of 1 × 105 cells per well in a 96-well plate and cultured for 2 h at 37 °C in an atmosphere of 5% CO2. 
The ovarian granulosa cells were then treated with DOI (1, 10, 100 nM)and incubated for 12 h. The cell 
culture medium was collected for the measurement of estradiol concentrations and cellular proteins 
were extracted for Western blot analysis. The experiments were approved by the Committee on the Use 
of Live Animals in Teaching and Research (CULATR 1824-09) of Li Ka Shing Faculty of Medicine, The 
University of Hong Kong.
Determination of acid, alkali and thermal stability, and chitinase activity of DOI. For the acid and alkali 
stability tests, DOI (10 nM) was treated with HCl (0.01, 0.1, and 1 M) or NaOH (0.01, 0.1, and 1 M) and 
incubated at 4 °C for 30 min to determine acid stability and alkali stability, respectively. The mixtures 
were then neutralized with either NaOH or HCl. The acid- or alkali-treated DOI was then added to 
the granulosa cells and incubated for 12 h. The cell culture medium was collected for the measure-
ment of estradiol concentrations. For the thermal stability test, DOI was incubated at 60 °C, 80 °C, or 
100 °C for 30 min. The heat-treated DOI was then added to the granulosa cells and incubated for 12 h. 
The cell culture medium was collected for the measurement of estrogen concentrations. The chitinase 
activity of DOI was measured using a Chitinase Assay Kit (# CS0980, Sigma-Aldrich) following the 
manufacturer’s instructions. Three substrates, 4-nitrophenyl N,N′ -diacetyl-β-D-chitobioside (N6133), 
4-nitrophenylN-acetyl-β-D-glucosaminide (9376), and 4-nitrophenyl β-D-N,N′ ,N′ ′ -triacetylchitotriose 
(N8638) were used to evaluate the exochitinase activity (chitobiosidase activity), exochitinase activity 
(β-N-acetylglucosaminidase activity), and endochitinase activity of DOI, respectively.
Evaluation of the viability of MCF-7 cells, OVCA-429 cells, mouse splenocytes, and rat ovarian granulosa 
cells after incubation with DOI by MTT assay. MCF-7 estrogen receptor positive-breast cancer cells 
www.nature.com/scientificreports/
1 5Scientific RepoRts | 5:10179 | DOi: 10.1038/srep10179
and OVCA-429 cancer cells with estrogen receptor were seeded at a density of 3 × 104 and 1.5 × 104 cells 
per well in 96-well microplates, respectively. They were serum starved for 24 h prior to drug treatment. 
Mouse splenocytes, isolated from BALB/c mice, were diluted with RPMI 1640 medium containing 15% 
fetal bovine serum and 1% penicillin-streptomycin and seeded at a density of 5 × 105 cells in 100 μL 
culture medium per well in 96-well microplates. The ovarian granulosa cells were prepared as described 
above. All cells were incubated at 37 °C in a humidified atmosphere with 5% CO2 for 24 h. For the gran-
ulosa cells and cancer cells, DOI in complete medium at a final concentration of 1, 10, and 100 nM was 
added and incubated for 48 h, whereas DOI in RPMI 1640 medium with 15% fetal bovine serum and 1% 
penicillin-streptomycin was added to the mouse splenocytes and incubated for 72 h. The cells were then 
incubated with 10 μL MTT solution (5 mg/mL) for 3 h. The formazan crystals were dissolved in DMSO 
and absorbance at O.D. 540 nm was measured using a microplate reader (Model 680; Bio-Rad, Hercules, 
California, USA). Percentage viability relative to the control was calculated.
Estradiol-stimulating effect of DOI in vitro. DOI (1, 10, 100 nM) was added to the ovarian gran-
ulosa cells and incubated for 12 h. The cell culture medium was collected for the measurement of estro-
gen concentrations and cellular proteins were extracted for Western blot analysis. Western blotting was 
performed on proteins from ovarian granulosa cells using specific anti-FSHR (sc-13935; Santa Cruz 
Biotechnology, Inc, USA) and anti-aromatase (sc-14245; Santa Cruz Biotechnology, Inc) antibodies. For 
the kinase inhibition assay, granulosa cells in serum-free DME/F12 1:1 medium supplemented with 
1% penicillin-streptomycin and 1% bovine serum albumin were seeded at a density of 1 × 106 cells in a 
24-well plate and were incubated at 37 °C in an atmosphere of 5% CO2 for 1 h. The cells were then treated 
with either 10 μM protein kinase A inhibitor (H-89), 20 μM protein kinase B inhibitor (LY-294002), or 
30 μM protein kinase C inhibitor (GF-109203X) for 1 h. DOI (10 nM) was then added and the cells were 
incubated for another 12 h. The cell culture medium was collected for the measurement of estrogen 
concentrations to evaluate the role of PKA, PKB, and PKC. In addition, to identify whether DOI binds 
to FSHR in an FSHR-attenuated ovarian granulosa cell model, ovarian granulosa cells were pretreated 
with 2 μg of FSHR antibody (sc-7798, Santa Cruz Biotechnology, Inc) as an FSHR antagonist for 30 min. 
The cells were then treated with DOI (0.1 and 0.01 μM), 1 μM Forskolin (Sigma-Aldrich) as a positive 
control, or 2 μg of FSHR antibody as a negative control for 12 h. The cell culture medium was collected 
for the measurement of estradiol concentrations.
Estradiol­stimulating effect of DOI in vivo. Animal model. All experiments were performed in 
accordance with relevant guidelines and regulations of the Committee on the Use of Live Animals in 
Teaching and Research (CULATR 1824-09) of Li Ka Shing Faculty of Medicine, The University of Hong 
Kong. Female SD rats (16 to 20 months old) with low serum estrogen levels were used as an animal 
model for aging. Female SD rats (8 months old) from the Laboratory Animal Unit, The University of 
Hong Kong, were maintained until they were 16 to 20 months old. The animals were housed in an 
air-conditioned room at an ambient temperature of 24 °C and relative humidity of 50%–65% under auto-
matic 12-h light/12-h dark cycles.
Drug administration and collection of serum and organs. Female SD rats (16 to 20 months old) were 
randomly divided into six groups (n = 6). Group 1 was the control group given intraperitoneal injections 
of phosphate buffered saline (PBS) only; Groups 2, 3, and 4 were given intraperitoneal injections of DOI 
at three different dosages (2.5, 5, and 10 mg/kg), respectively; and Group 5 received an oral adminis-
tration of Premarin (12.4 mg/kg). Each rat was treated daily for 6 weeks. Blood samples were collected 
from the tail vein once every 2 weeks for the measurement of serum estrogen and progesterone levels. 
At the end of the experiment, the ovaries, the 1st to 6th lumbar vertebrae, brains, and breast tissues were 
collected and stored at −80 °C for further analysis. Their final body weight and final ovarian weight were 
also measured.
Detection of hormone levels. Estradiol and progesterone levels were measured using commercially avail-
able electro-chemiluminescence immunoassay (ECLIA) kits (Estradiol II #03000079 and Progesterone II 
#12145383; Roche Diagnostics, IN, USA) on a Elecsys 2010 autoanalyzer (Roche Diagnostics) following 
the manufacturer’s instructions.
Determination of estrogen-related gene expression by real time PCR. Total RNA was extracted 
from rat ovarian granulosa cells and ovaries using the High Pure RNA Isolation Kit (Roche 
Applied Science) following the manufacturer’s instructions. cDNA was synthesized from total 
RNA using the First Strand cDNA Synthesis Kit (Fermentas) following the manufacturer’s 
instructions. Real time PCR was performed using a LightCycler 480 Real-Time PCR system 
(Roche Applied Science). Primers were as follows: ovarian CYP-19 (Forward: 5′ 
GAGAGTTCATGAGAGTCTGGATCA, Reverse: 5′ GATATAGTTGCTGTGCTTCATCA), ovar-
ian FSHR (Forward: 5′ GAAAGGATCATTTGCTGGATTT, Reverse: 5′ CTTCCAAGACAT 
CATTCTGAGAGA), ovarian PKA (Forward: 5′ TGGATGTGATCGGGGAAA, Reverse: 5′ 
AAGCTGTCGGCCTTTTCA), ovarian PKB (Forward: 5′ AAAACTTTCTTCGTCCACACG, Reverse: 
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5′ GGACTGCTCTGGTACTGTTGC), and ovarian PKC (Forward: 5′ GCATAGACTGGGACCTGCTT, 
Reverse: 5′ CCAGGCCATAGTCATCTGTG).
Determination of estrogen-related proteins by Western blot analysis. Proteins were extracted from rat 
ovarian granulosa cells, ovaries and breast tissues, and MCF-7 breast cancer cells using RIPA buffer 
(Sigma-Aldrich) with complete protease inhibitor cocktail tablets (Roche Applied Science). Denatured 
proteins (20 μg per sample) were separated on SDS-PAGE and transferred to PVDF membranes. For pro-
teins from ovarian granulosa cells and ovaries, immunoblotting was performed using specific anti-FSHR 
(sc-13935; Santa Cruz Biotechnology, Inc), anti-aromatase (sc-14245; Santa Cruz Biotechnology, Inc), 
anti-phospho-PKA (#04-404; Upstate, Millipore), anti-p-AKT1/2/3 (ser 473)-R (sc-7985-R; Santa 
Cruz Biotechnology, Inc) and anti-phospho-PKC (Thr555/Thr563; Upstate, Millipore) antibodies with 
anti-GAPDH antibody as the internal standard. After incubation with horseradish peroxidase-conjugated 
secondary antibody, the chemiluminescence (GE Bio-health) was detected with the Bio-Rad Chemi Doc™ 
EQ densitometer (Bio-Rad) and quantified by Bio-Rad Quantity One 1-D Analysis software (Bio-Rad).
Measurement of bone mineral density and microarchitecture by microCT scanning. Sprague Dawley rats 
were treated with DOI for 6 weeks. Lumbar vertebrae including soft tissue were harvested and wrapped 
in normal saline gauze (0.9%) and stored at −80 °C until use. Bone status was evaluated using an In Viva 
MicroCT 40 computed tomography system (Scanco Medical, Bassersdorf, Switzerland). For image acqui-
sition, the thawed lumbar vertebrae specimens wrapped in saline gauze were placed in a sample holder 
and the long axis was aligned with the axis of rotation of the X-ray gantry. A scout view was obtained, 
which was used to identify the vertebra L2 to determine the scanning location. A set of 100 contiguous 
axial slices at an isotropic resolution of 21 μm was prescribed at the L2 mid-vertebral body. Exposure 
parameters were set at X-ray tube peak voltage of 70 kVp, tube current of 114 μA, and integration time 
of 300 ms. Calibration of X-ray attenuation to bone mineral density (mg/cc of hydroxyapatite, HA) on 
the microCT scanner was carried out weekly using a standardized phantom. For Image processing and 
analysis, a Gaussian filter (support = 2 and sigma = 1.2) was used to reduce the image noise. Precise 
contouring was performed in each of the slices by manually drawing the region of interest a few voxels 
away from the endocortical boundary. This was then followed by segmentation using a global threshold 
of 250 for all the study groups to separate the mineralized tissues from non-mineralized tissues. Volume 
rendering of the segmented slices was performed to provide a three-dimensional (3D) image. The appar-
ent trabecular bone mineral density and its bone microarchitecture were automatically evaluated using 
the built-in program of the microCT system using the model-independent direct 3D morphometry. 
The bone microarchitecture including apparent trabecular bone mineral density, bone volume fraction, 
trabecular number, trabecular thickness, trabecular separation, and structural model index were deter-
mined (see Supplementary Table S5 for an explanation of the bone microarchitecture parameters)67.
Detection of the protein levels of BDNF and TrkB gp145. The protein levels of BDNF in rat prefrontal 
cortex and hippocampus were measured using a BDNF Sandwich ELISA Kit (#CYT306; Millipore) fol-
lowing the manufacturer’s instructions. The protein expression levels of BDNF were normalized using the 
total protein concentration of the individual samples. Immunoblotting was performed using anti-TrkB 
receptor antibody (sc-8316; Santa Cruz Biotechnology, Inc) for proteins from the prefrontal cortex with 
anti-GAPDH antibody as the internal standard. After incubation with horseradish peroxidase-conjugated 
secondary antibody, the chemiluminescence (GE Bio-health) was detected using a Bio-Rad Chemi 
Doc™ EQ densitometer (Bio-Rad) and quantified by the Bio-Rad Quantity One 1-D Analysis software 
(Bio-Rad).
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